{"prompt": "['NET-PRO Protocol v1.3', 'April 2022', '5.5.2.', 'Direct-to-patient communication (e.g., MyChart, other EMR messaging, etc.)', '23', '5.5.3.', 'Letter', '23', '5.5.4.', 'Study packets', '23', '5.6.', 'Patient recruitment contacts and recruitment materials - follow-up contacts', '23', '5.7.', 'Enrollment via NET-PRO PHR research portal', '24', '5.7.1.', 'Patient-Reported Eligibility Criteria', '24', '5.7.2.', 'Eligibility outcomes', '24', '5.7.3.', 'Review and Signing Informed Consent Document', '25', '5.8.', 'Enrollment via Study Packet', '25', '5.9.', 'Enrollment Monitoring and Reporting', '25', '5.10.', 'Post-consent study procedures', '25', '5.10.1.', 'Baseline survey', '26', '5.10.1.1.', 'Participation via the NET-PRO PHR', '26', '5.10.1.2.', 'Participation via paper study packet', '26', '5.10.2.', 'UICC Reminder Contacts', '26', '5.10.3.', 'Follow-up surveys', '26', '5.10.4.', 'Subject Compensation', '27', '5.11.', 'Post-enrollment monitoring', '27', '5.12.', 'Population of CDM PCORnet_TRIAL table', '27', '5.13.', 'Data Crosswalks', '27', '6.', 'DATA SOURCES', '29', '6.1.', 'EMR data - Clinical and billing data from the PCORnet CDM', '29', '6.2.', 'EMR data - Abstracted medical record data (per chart review)', '30', '6.2.1.', 'Chart review form', '30', '6.2.2.', 'Chart review training', '30', '6.3.', 'Patient surveys', '30', '6.4.', 'Patient study website navigation', '31', '7.', 'STUDY OUTCOMES', '32', '7.1.', 'Primary Outcomes', '32', '7.2.', 'Secondary Outcomes', '33', '8.', 'COMPARATORS', '36', '8.1.', 'Aim 1 (Frequency of treatment regimens)', '36', '8.2.', 'Aim 2 (Treatment selection and outcomes)', '36', '8.3.', 'Aim 3 (Comparative effectiveness of PRRT regimens)', '36', '9.', 'STATISTICAL ANALYSIS PLAN', '37', '5']['NET-PRO Protocol v1.3', 'April 2022', '9.1.', 'General Statistical Approach', '37', '9.1.1.', 'Aim 1', '37', '9.1.2.', 'Aim 2', '37', '9.1.3.', 'Aim 3', '37', '9.2.', 'Sample Size and Power', '37', '9.2.1.', 'Aim 1', '37', '9.2.2.', 'Aim 2', '38', '9.2.3.', 'Aim 3', '38', '9.3.', 'Addressing confounding', '39', '9.4.', 'Addressing clustering of site', '39', '9.5.', 'Handling missing data', '39', '10.', 'DATA MONITORING & QUALITY CONTROL', '40', '10.1.', 'Methods to establish validity of the NET Computable Phenotype', '40', '10.2.', 'Details on population of tumor table data', '40', '10.2.1.', 'Tumor table quality scripts', '41', '10.3.', 'Evaluating and Adapting the NET Patient Health Record (NET PHR)', '41', '11.', 'NET-PRO TIMELINE', '43', '12.', 'Engagement and sharing of results customized to local settings of care', '48', '13.', 'STUDY GOVERNANCE AND POLICIES', '49', '13.1.', 'Study leadership and Management', '49', '13.2.', 'University of Iowa Coordinating Center (UICC) Roles and Responsibilities', '49', '13.3.', 'NET-PRO Steering Committee', '49', '13.3.1.', 'Primary functions of the Steering Committee', '49', '13.4.', 'Role and Purpose of the Stakeholder Committees', '52', '13.4.1.', 'NET-PRO Stakeholder Committees - Membership and Affiliations', '53', '13.5.', 'Voting at committee meetings', '55', '13.6.', 'Attendance at committee meetings', '55', '13.6.1.', 'Co-Chairs', '55', '13.6.2.', 'Members', '55', '13.7.', 'Resolution of disputes', '56', '14.', 'STUDY RESPONSIBILITIES', '57', '14.1.', 'Investigator Responsibility/Performance', '57', '14.2.', 'Site communications', '57', '14.3.', 'Study documentation', '57', '14.4.', 'Protocol Deviations', '57', '6']\n\n###\n\n", "completion": "END"}